Brainstorming II: What three radical changes might, through the agency of R&D, take place in this industry by the end of the century?

This article is part of the Tobacco portal on Sourcewatch funded from 2006 - 2009 by the American Legacy Foundation.

Brainstorming II: What three radical changes might, through the agency of R&D, take place in this industry by the end of the century?

In this 1980 report/meeting minutes, Dr. Robin A. Crellin of British American Tobacco (BAT) likens the company's role to that of a drug company with the duty of supplying the world's increasing appetite for "mood-affecting" drugs.

2. Drug Diversification In a world of increased government intervention, BAT should learn to look at itself as a drug company rather than as a tobacco company. The mood affecting drug requirements of the population will in the future increase but the range of requirements will encompass tranquillisers e.g. valium, endorphin/enkephalin (brain opiates), marijuana, nicotine analogues, etc. At present the taking of many of these drugs is either medically prescribed or regarded as deviant behavior, but could be "socialised" like alcoholic drinking and tobacco smoking. The diversification programme would have to include (i) what to administer, (ii) how to administer it, and (iii) how to encourage social acceptability. Initial research might be pursued through contracts followed up through the purchase of a drug company.

Title: Brainstorming II
Author: Robin A. Crellin BAT UK & Export
Document date:19800411
Page count:2
Bates number:109884190-109884191
Bookmark as: http://bat.library.ucsf.edu/tid/gum24a99